KR19990087793A - 러크-8로 표시된 싸이토킨 - Google Patents

러크-8로 표시된 싸이토킨 Download PDF

Info

Publication number
KR19990087793A
KR19990087793A KR1019980707281A KR19980707281A KR19990087793A KR 19990087793 A KR19990087793 A KR 19990087793A KR 1019980707281 A KR1019980707281 A KR 1019980707281A KR 19980707281 A KR19980707281 A KR 19980707281A KR 19990087793 A KR19990087793 A KR 19990087793A
Authority
KR
South Korea
Prior art keywords
lurk
polypeptide
seq
amino acid
residues
Prior art date
Application number
KR1019980707281A
Other languages
English (en)
Korean (ko)
Inventor
더글라스 피. 체레티
Original Assignee
크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카
임뮤넥스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카, 임뮤넥스 코포레이션 filed Critical 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카
Publication of KR19990087793A publication Critical patent/KR19990087793A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1019980707281A 1996-03-21 1997-03-19 러크-8로 표시된 싸이토킨 KR19990087793A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62114696A 1996-03-21 1996-03-21
US8/621,146 1996-03-21

Publications (1)

Publication Number Publication Date
KR19990087793A true KR19990087793A (ko) 1999-12-27

Family

ID=24488927

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980707281A KR19990087793A (ko) 1996-03-21 1997-03-19 러크-8로 표시된 싸이토킨

Country Status (7)

Country Link
EP (1) EP0904287A3 (fr)
JP (1) JP2001521368A (fr)
KR (1) KR19990087793A (fr)
AU (1) AU2538697A (fr)
IL (1) IL125919A0 (fr)
NO (1) NO984233L (fr)
WO (1) WO1997036919A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004091A1 (fr) * 1995-07-20 1997-02-06 Amrad Operations Pty. Ltd. Nouveaux ligands de recepteurs et sequences genetiques codant ces ligands
WO1997015667A1 (fr) * 1995-10-25 1997-05-01 Regeneron Pharmaceuticals, Inc. Ligands biologiquement actifs de la famille des eph
AU2003268345A1 (en) 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
EP1841790B1 (fr) 2005-01-27 2010-11-03 The Burnham Institute Peptides de liaison aux recepteurs ephb

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
ATE346498T1 (de) * 1994-10-05 2006-12-15 Immunex Corp Als lerk6 bezeichnetes cytokin
ES2240981T3 (es) * 1994-12-06 2005-10-16 Immunex Corporation Citocina denominada lerk-7.

Also Published As

Publication number Publication date
IL125919A0 (en) 1999-04-11
JP2001521368A (ja) 2001-11-06
EP0904287A2 (fr) 1999-03-31
NO984233D0 (no) 1998-09-14
NO984233L (no) 1998-11-23
AU2538697A (en) 1997-10-22
EP0904287A3 (fr) 2000-12-20
WO1997036919A2 (fr) 1997-10-09
WO1997036919A3 (fr) 2000-10-12

Similar Documents

Publication Publication Date Title
JP4392058B2 (ja) オンコスタチンｍ受容体
EP0871702B1 (fr) Cytokine designee par lerk-7
US6479459B1 (en) Cytokine designated lerk-5
US5674704A (en) Cytokine designated 4-IBB ligand
US7329740B2 (en) Flk-1 binding protein
US6355779B1 (en) Cytokine designated 4-1BB ligand antibodies and human receptor that binds thereto
US7625710B2 (en) Methods for determining 2F1-binding compounds
US7138500B1 (en) Antibodies to human 4-1BB
JP2003532365A (ja) Ｌｅｒｋ−６と称されるサイトカイン
JP2001510042A (ja) Ｔｒａｉｌ受容体
JP2002507127A (ja) Ｔｒａｉｌに結合するタンパク質
US6268482B1 (en) Recombinant cytokine designated LERK-6
KR19990087793A (ko) 러크-8로 표시된 싸이토킨
US6994989B1 (en) FLK-1 binding proteins
MXPA98007441A (en) Desired cytokine ler

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid